Subscribe
agreement-istock-480052842_mediaphotos
mediaphotos / iStockphoto.com
7 April 2017Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem (sodium oxybate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility